Published in Urol Oncol on September 20, 2011
Standardizing the experimental conditions for using urine in NMR-based metabolomic studies with a particular focus on diagnostic studies: a review. Metabolomics (2014) 1.24
Review: toxicometabolomics. J Appl Toxicol (2013) 1.03
Untargeted plasma metabolite profiling reveals the broad systemic consequences of xanthine oxidoreductase inactivation in mice. PLoS One (2012) 1.03
Big data: the next frontier for innovation in therapeutics and healthcare. Expert Rev Clin Pharmacol (2014) 0.97
A review of applications of metabolomics in cancer. Metabolites (2013) 0.96
Application of Holistic Liquid Chromatography-High Resolution Mass Spectrometry Based Urinary Metabolomics for Prostate Cancer Detection and Biomarker Discovery. PLoS One (2013) 0.94
Global metabolomic analysis of human saliva and plasma from healthy and diabetic subjects, with and without periodontal disease. PLoS One (2014) 0.94
Potential biofluid markers and treatment targets for renal cell carcinoma. Nat Rev Urol (2013) 0.91
Mealtime, temporal, and daily variability of the human urinary and plasma metabolomes in a tightly controlled environment. PLoS One (2014) 0.88
Use of Charged Nanoparticles in NMR-Based Metabolomics for Spectral Simplification and Improved Metabolite Identification. Anal Chem (2015) 0.86
Bladder cancer biomarker discovery using global metabolomic profiling of urine. PLoS One (2014) 0.85
Applications of metabolomics in cancer research. J Carcinog (2013) 0.85
Perspectives on systems biology applications in diabetic kidney disease. J Cardiovasc Transl Res (2012) 0.84
Potential role of metabolomics in diagnosis and surveillance of gastric cancer. World J Gastroenterol (2014) 0.84
Urinary signatures of Renal Cell Carcinoma investigated by peptidomic approaches. PLoS One (2014) 0.81
Cancer Metabolomics and the Human Metabolome Database. Metabolites (2016) 0.80
Relative quantification of amine-containing metabolites using isobaric N,N-dimethyl leucine (DiLeu) reagents via LC-ESI-MS/MS and CE-ESI-MS/MS. Analyst (2015) 0.79
Personalized Cardiovascular Disease Prediction and Treatment-A Review of Existing Strategies and Novel Systems Medicine Tools. Front Physiol (2016) 0.78
Biomarker Discovery and Translation in Metabolomics. Curr Metabolomics (2016) 0.77
A Statistical Analysis of the Effects of Urease Pre-treatment on the Measurement of the Urinary Metabolome by Gas Chromatography-Mass Spectrometry. Metabolomics (2014) 0.76
Ambient ionization mass spectrometric analysis of human surgical specimens to distinguish renal cell carcinoma from healthy renal tissue. Anal Bioanal Chem (2016) 0.76
Urine and Serum Metabolomics Analyses May Distinguish between Stages of Renal Cell Carcinoma. Metabolites (2017) 0.75
Circulating biomarkers in renal cell carcinoma: the link between microRNAs and extracellular vesicles, where are we now? J Kidney Cancer VHL (2014) 0.75
Urinary volatile organic compounds as potential biomarkers for renal cell carcinoma. Biomed Rep (2016) 0.75
Tissue metabolic profiling of human gastric cancer assessed by (1)H NMR. BMC Cancer (2016) 0.75
Differential toxicity of arsenic on renal oxidative damage and urinary metabolic profiles in normal and diabetic mice. Environ Sci Pollut Res Int (2017) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
A comprehensive urinary metabolomic approach for identifying kidney cancerr. Anal Biochem (2007) 3.14
Metabolomics: building on a century of biochemistry to guide human health. Metabolomics (2005) 3.01
Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol Cell Proteomics (2008) 1.78
A metabolomics approach using juvenile cystic mice to identify urinary biomarkers and altered pathways in polycystic kidney disease. Am J Physiol Renal Physiol (2010) 1.63
Targeted metabolomics for biomarker discovery. Angew Chem Int Ed Engl (2010) 1.45
Grade-dependent proteomics characterization of kidney cancer. Mol Cell Proteomics (2009) 1.41
Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer. OMICS (2011) 1.23
Application of NMR in plant metabolomics: techniques, problems and prospects. Phytochem Anal (2009) 1.17
1H NMR spectra of normal urines: reference ranges of the major metabolites. Clin Chim Acta (1997) 1.00
Quality of life predicts progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib versus interferon alfa. J Oncol Pract (2009) 0.99
Toxicometabolomics of urinary biomarkers for human gastric cancer in a mouse model. J Toxicol Environ Health A (2010) 0.92
Mouse urinary biomarkers provide signatures of maturation, diet, stress level, and diurnal rhythm. Chem Senses (2010) 0.90
Proteomic analysis of clear cell renal cell carcinoma. Identification of potential tumor markers. Saudi Med J (2010) 0.89
A comprehensive urinary metabolomic approach for identifying kidney cancerr. Anal Biochem (2007) 3.14
CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth. J Urol (2012) 2.05
Kidney tumor biomarkers revealed by simultaneous multiple matrix metabolomics analysis. Cancer Res (2012) 1.81
Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol Cell Proteomics (2008) 1.78
Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol Cancer (2006) 1.78
CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. J Clin Invest (2011) 1.71
Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis. Proc Natl Acad Sci U S A (2013) 1.66
Exogenous attenuation of p21(Waf1/Cip1) decreases mesangial cell hypertrophy as a result of hyperglycemia and IGF-1. J Am Soc Nephrol (2004) 1.65
A metabolomics approach using juvenile cystic mice to identify urinary biomarkers and altered pathways in polycystic kidney disease. Am J Physiol Renal Physiol (2010) 1.63
Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. Proc Natl Acad Sci U S A (2002) 1.51
Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model. J Cardiovasc Pharmacol (2008) 1.42
Grade-dependent proteomics characterization of kidney cancer. Mol Cell Proteomics (2009) 1.41
Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy. Cancer Biol Ther (2011) 1.30
Vascular localization of soluble epoxide hydrolase in the human kidney. Am J Physiol Renal Physiol (2003) 1.25
Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer. OMICS (2011) 1.23
Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo. Mol Cancer Ther (2009) 1.22
Urinary acylcarnitines are altered in human kidney cancer. Int J Cancer (2011) 1.14
p21 is decreased in polycystic kidney disease and leads to increased epithelial cell cycle progression: roscovitine augments p21 levels. BMC Nephrol (2007) 1.11
An antisense oligodeoxynucleotide to p21(Waf1/Cip1) causes apoptosis in human breast cancer cells. Mol Cancer Ther (2003) 1.11
Individual variation in lipidomic profiles of healthy subjects in response to omega-3 Fatty acids. PLoS One (2013) 1.10
Serum oxylipin profiles in IgA nephropathy patients reflect kidney functional alterations. Metabolomics (2012) 1.09
New opportunities from the cancer metabolome. Clin Chem (2012) 1.06
High throughput screening of a small molecule one-bead-one-compound combinatorial library to identify attenuators of p21 as chemotherapy sensitizers. Cancer Biol Ther (2008) 1.03
Cytosolic p21Waf1/Cip1 increases cell cycle transit in vascular smooth muscle cells. Cell Signal (2004) 1.03
Stability of miRNA in human urine supports its biomarker potential. Biomark Med (2013) 1.02
Anti-inflammatory effects of ω-3 polyunsaturated fatty acids and soluble epoxide hydrolase inhibitors in angiotensin-II-dependent hypertension. J Cardiovasc Pharmacol (2013) 0.99
BMP-2 inhibits proliferation of human aortic smooth muscle cells via p21Cip1/Waf1. Am J Physiol Endocrinol Metab (2003) 0.98
Urine dipstick analysis for identification of runners susceptible to acute kidney injury following an ultramarathon. J Sports Sci (2012) 0.94
Potential biofluid markers and treatment targets for renal cell carcinoma. Nat Rev Urol (2013) 0.91
Attenuation of PTEN increases p21 stability and cytosolic localization in kidney cancer cells: a potential mechanism of apoptosis resistance. Mol Cancer (2007) 0.91
Antisense attenuation of p21 sensitizes kidney cancer to apoptosis in response to conventional DNA damaging chemotherapy associated with enhancement of phospho-p53. J Urol (2008) 0.89
Attenuation of vascular smooth muscle cell proliferation by 1-cyclohexyl-3-dodecyl urea is independent of soluble epoxide hydrolase inhibition. J Pharmacol Exp Ther (2005) 0.89
Inhibition of PPARα induces cell cycle arrest and apoptosis, and synergizes with glycolysis inhibition in kidney cancer cells. PLoS One (2013) 0.86
Rapid and quantitative DNA analysis of genetic mutations for polycystic kidney disease (PKD) using magnetic/luminescent nanoparticles. Anal Bioanal Chem (2008) 0.86
A novel p21 attenuator which is structurally related to sorafenib. Cancer Biol Ther (2013) 0.83
Exercise-associated hyponatremia with exertional rhabdomyolysis: importance of proper treatment. Clin Nephrol (2015) 0.81
Targeting the PI3K-Akt pathway in kidney cancer. Expert Rev Anticancer Ther (2007) 0.81
Disparate effects of roscovitine on renal tubular epithelial cell apoptosis and senescence: implications for autosomal dominant polycystic kidney disease. Am J Nephrol (2008) 0.79
Effects of imputation on correlation: implications for analysis of mass spectrometry data from multiple biological matrices. Brief Bioinform (2016) 0.79
Pharmacological inhibition of cyclin dependent kinases causes p53 dependent apoptosis in renal cell carcinoma. J Urol (2010) 0.79
Atorvastatin restricts HIV replication in CD4+ T cells by upregulation of p21. AIDS (2016) 0.78
Small-molecule inhibitors of p21 as novel therapeutics for chemotherapy-resistant kidney cancer. Future Med Chem (2013) 0.77
Biological evaluation of a novel sorafenib analogue, t-CUPM. Cancer Chemother Pharmacol (2014) 0.77
TNF-alpha-mediated apoptosis in vascular smooth muscle cells requires p73. Am J Physiol Cell Physiol (2005) 0.77
Overexpression of p73 causes apoptosis in vascular smooth muscle cells. Am J Physiol Cell Physiol (2002) 0.77
Novel sorafenib-based structural analogues: in-vitro anticancer evaluation of t-MTUCB and t-AUCMB. Anticancer Drugs (2014) 0.76
Applications of metabolomics for kidney disease research: from biomarkers to therapeutic targets. Organogenesis (2013) 0.75
Does Acute Kidney Injury From an Ultramarathon Increase the Risk for Greater Subsequent Injury? Clin J Sport Med (2016) 0.75
From bead to flask: Synthesis of a complex β-amido-amide for probe-development studies. Beilstein J Org Chem (2013) 0.75
Biomarkers in IgA nephropathy. Biomark Med (2014) 0.75